SKYTROFA (Specialised Therapeutics Pharma Pty Ltd)
Product name
SKYTROFA
Date registered
Evaluation commenced
Decision date
Approval time
202 (255 working days)
Active ingredients
lonapegsomatropin
Registration type
NCE/ NBE
Indication
Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion.